Watson Pharmaceuticals

Watson Pharmaceuticals was a generic drug manufacturer. It later became part of Actavis, and that business later became part of Teva. This profile is Watson, the company named in the FTC's Endo matter, not the later combined generic group. The corporate sequence explains why Watson and the library's Teva id, tevapharm, can appear in one story and still be two respondents.

The FTC challenged pay-for-delay settlements involving Endo and its Lidoderm patch. Pay-for-delay means the brand compensates a generic challenger to hold the generic off the market. Watson was on that generic side. The matter settled. A settlement ends the FTC case on agreed terms. It is not a damages award this profile can price, and no dollar figure is given.

Library status is settled. The people who pay are patients using the brand patch and the insurers behind them. Every month the generic stays off the shelf is a month of brand pricing. Watson's later place inside Teva does not move those months.

Watson is the generic manufacturer in the Endo pay-for-delay file, later absorbed into Actavis and then Teva.

Lidoderm is the brand product the generic entry was postponed against.

The recorded outcome is a settlement, without a dollar figure in this profile.

Patients and health plans paid brand prices for the patch while the generic Watson could have sold was delayed.

A pharmacist's substitution, the ordinary way a generic reaches a patient, had nothing to substitute until the delay ended.